Financing dependence and dilution
The company raised capital through a private placement and issued warrants, indicating reliance on external funding.
- Scope
- Common share issuance and warrant overhang
- Materiality
- high
Family Office Of America, Inc.
Family Office of America, Inc. is a U.S.-based medical device company that appears to be in an early commercial stage, with filings showing capital raising and equity-based compensation activity rather than established operating revenue. The company’s disclosed history includes a subsidiary relationship with mPathix Health, Inc. and a license agreement tied to Life Care Medical Devices Limited, suggesting a product-development and commercialization model in surgical and medical instruments.
100,0 %
−222,2 %
0.47
0.47
| % | |
|---|---|
| Surgical & medical instruments | 70% Core medical device products and apparatus intended for clinical or procedural use. |
| Licensed device technology | 20% Technology rights and know-how obtained through licensing arrangements for medical products. |
| Development-stage services | 10% Internal development, regulatory preparation, and commercialization support around device launch. |
The company’s likely customers are healthcare providers, distributors, and other commercial partners that buy or...
- Healthcare providersprimary
Hospitals, clinics, and procedural centers that would purchase or use medical devices in care delivery.
- Medical distributorssecondary
Channel partners that could buy devices in bulk and resell into healthcare markets.
- Licensing/commercial partnerssecondary
Partners that may license technology or support product commercialization and market access.
- Accredited investorsprimary
Investors providing capital through private placements to fund operations and development.
The company is headquartered in the United States, and the available filings do not disclose meaningful country-level...
- •United States is the disclosed home market and reporting base
- •No country-level revenue disclosure was provided in the excerpts
- •Medical device commercialization would be shaped by U.S. regulation
- •Future international expansion is not yet evidenced in the filings
The company’s near-term strategy appears focused on financing the business, advancing medical device-related assets,...
01
Complete financing and preserve working capitalshort-term
The company is still funding development and corporate activity through private placements.
02
Advance licensed medical device assetsmedium-term
Licensed technology can shorten time to market versus building products from scratch.
03
Establish a commercial platformmedium-term
Sustainable value depends on converting development-stage assets into marketable products.
The company faces classic development-stage medical device risks: limited operating history, dependence on external...
Commercialization failure
Medical device businesses must convert development assets into clinically adopted products, which is uncertain.
- Scope
- Licensed device technology and product launch execution
- Materiality
- high
Regulatory and compliance risk
Surgical and medical instruments are subject to healthcare regulation, quality systems, and market clearance requirements.
- Scope
- Product approval, labeling, and post-market compliance
- Materiality
- high
Third-party licensing dependence
The company references a license agreement, so access to technology may depend on contractual terms and counterparties.
- Scope
- mPathix Health / Life Care Medical Devices Limited arrangement
- Materiality
- medium
Warrant valuation and remeasurement
Can create non-cash expense and earnings volatility
Equity issuance accounting
Changes shareholders' equity and per-share metrics
Share-based consulting compensation
Affects operating expenses and APIC
: 28.4.2026